In the following video, Motley Fool health-care analyst David Williamson looks at pharmaceutical company Corcept (CORT +2.40%) for being one of the top-performing health-care stocks in January. Although shares were ripped in half when the company failed to launch its Cushing's disease drug Korlym in 2012, while competitor Novartis (NVS +0.67%) did receive FDA approval for its drug in this space, Signifor, Corcept was able to rebound in January by up to 52%. David tells us why the amount of cash Corcept has on hand means the company has plenty of time to get things right next time.
January Top 10: Corcept
By Dave Williamson – Feb 5, 2013 at 4:40PM
NASDAQ: CORT
Corcept Therapeutics
Market Cap
$7.9B
Today's Change
(2.40%) $1.77
Current Price
$75.49
Price as of November 10, 2025 at 4:00 PM ET
A look back at January's most incredible health-care stocks.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid